Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Welcome and Introduction to Vi3C

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement

Jul

14

Today In Oncology

MRD-Guided Therapy With Ibrutinib-Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia

Metformin in Metastatic Prostate Cancer

Teclistamab for High-Risk, Heavily Pretreated Multiple Myeloma Real-World Data

Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1-KMT2A Alterations

Dual Menin and KAT6A-7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

Advertisement

© 2025 HSP News Service, L.L.C.